Elutia Sells Off Orthobiologics Business Unit

Elutia, formerly branded as Aziyo Biologics, announced the divestiture of its orthobiologics business unit to Berkeley Biologics/Berkeley Advanced Biomaterials. Elutia will receive cash proceeds of up to $35 million, comprising an upfront payment at closing of $15 million plus potential earnout payments of up to $20 million over five years.


document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us